Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biomarker Profile of Colorectal Cancer: Current Findings and Future Perspective Publisher



Hoseini SH1 ; Enayati P2 ; Nazari M3, 4 ; Babakhanzadeh E5 ; Rastgoo M6 ; Sohrabi NB7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Biological Sciences Department, Northern Illinois University, DeKalb, IL, United States
  3. 3. Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. P.O. Box, Tehran, 64155-65117, Iran
  5. 5. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Microbiology, Shiraz Islamic Azad University, Shiraz, Iran
  7. 7. School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Journal of Gastrointestinal Cancer Published:2024


Abstract

Objective: Breakthroughs in omics technology have led to a deeper understanding of the fundamental molecular changes that play a critical role in the development and progression of cancer. This review delves into the hidden molecular drivers of colorectal cancer (CRC), offering potential for clinical translation through novel biomarkers and personalized therapies. Methods: We summarizes recent studies utilizing various omics approaches, including genomics, transcriptomics, proteomics, epigenomics, metabolomics and data integration with computational algorithms, to investigate CRC. Results: Integrating multi-omics data in colorectal cancer research unlocks hidden biological insights, revealing new pathways and mechanisms. This powerful approach not only identifies potential biomarkers for personalized prognosis, diagnosis, and treatment, but also predicts patient response to specific therapies, while computational tools illuminate the landscape by deciphering complex datasets. Conclusions: Future research should prioritize validating promising biomarkers and seamlessly translating them into clinical practice, ultimately propelling personalized CRC management to new heights. © 2024, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.